ARCA biopharma, Inc. and Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors of ARCA have mutually agreed to conclude Dr. Bristow's employment and service as a director, effective April 3, 2024. In connection with Dr. Bristow's separation, ARCA and Dr. Bristow entered into a separation agreement on April 3, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | +1.46% | -4.66% | +104.71% |
Apr. 25 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+104.71% | 49.74M | |
-3.18% | 102B | |
+1.42% | 96.29B | |
+2.13% | 22.18B | |
-15.82% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.39% | 16.36B | |
+4.55% | 13.97B | |
+32.37% | 12.17B |
- Stock Market
- Equities
- ABIO Stock
- News ARCA biopharma, Inc.
- ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer